Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Gastric pH on Acalabrutinib PK
NCT04905043Phase 1Completed
- Sponsor
- Acerta Pharma
- Start
- Jun 2016
- Primary completion
- Jul 2016
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of acalabrutinib tablet (Variant 1) in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Acerta Pharma. Primary endpoints: Effect of Gastric pH and Emptying Rate on Acalabrutinib PK Parameters, Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Measurable Concentration at 24 hours and 2 more. Started Jun 2016; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04905043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04905043.